Advertisement
SNDL vs ZTS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SNDL is a Hold and ZTS is a Hold.
SNDL in downward trend: price dove below 50-day moving average on September 30, 2026
SNDL moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend. In 34 of 38 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNDL as a result. In 72 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for SNDL turned negative on September 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 38 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
The 10-day moving average for SNDL crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNDL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for SNDL entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
SNDL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.455) is normal, around the industry mean (5.109). P/E Ratio (3.536) is within average values for comparable stocks, (99.123). SNDL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.650). Dividend Yield (0.000) settles around the average of (0.029) among similar stocks. P/S Ratio (0.536) is also within normal values, averaging (4.786).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. SNDL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNDL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 100, placing this stock worse than average.
ZTS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ZTS turned positive on October 06, 2026. Looking at past instances where ZTS's MACD turned positive, the stock continued to rise in 33 of 48 cases over the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on ZTS as a result. In 44 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 49%.
ZTS moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZTS advanced for three days, in 148 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for ZTS crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
ZTS broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ZTS entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.372) is normal, around the industry mean (43.873). P/E Ratio (11.653) is within average values for comparable stocks, (141.710). ZTS's Projected Growth (PEG Ratio) (6.647) is slightly higher than the industry average of (2.152). ZTS has a moderately high Dividend Yield (0.029) as compared to the industry average of (0.005). P/S Ratio (3.299) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 18 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. ZTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
SNDL | ZTS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 43 Fair valued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 91 | 18 | |
PRICE GROWTH RATING 1..100 | 79 | 63 | |
P/E GROWTH RATING 1..100 | 86 | 93 | |
SEASONALITY SCORE 1..100 | 11 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZTS's Valuation (10) in the Pharmaceuticals Generic industry is somewhat better than the same rating for SNDL (43) in the null industry. This means that ZTS’s stock grew somewhat faster than SNDL’s over the last 12 months.
ZTS's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as SNDL (100) in the null industry. This means that ZTS’s stock grew similarly to SNDL’s over the last 12 months.
ZTS's SMR Rating (18) in the Pharmaceuticals Generic industry is significantly better than the same rating for SNDL (91) in the null industry. This means that ZTS’s stock grew significantly faster than SNDL’s over the last 12 months.
ZTS's Price Growth Rating (63) in the Pharmaceuticals Generic industry is in the same range as SNDL (79) in the null industry. This means that ZTS’s stock grew similarly to SNDL’s over the last 12 months.
SNDL's P/E Growth Rating (86) in the null industry is in the same range as ZTS (93) in the Pharmaceuticals Generic industry. This means that SNDL’s stock grew similarly to ZTS’s over the last 12 months.
| SNDL | ZTS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 88% | N/A |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 69% |
| Momentum ODDS (%) | 1 day ago 82% | 1 day ago 49% |
| MACD ODDS (%) | 2 days ago 86% | 1 day ago 69% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 55% |
| TrendMonth ODDS (%) | 1 day ago 81% | 1 day ago 50% |
| Advances ODDS (%) | N/A | 3 days ago 51% |
| Declines ODDS (%) | 1 day ago 82% | 14 days ago 62% |
| BollingerBands ODDS (%) | 1 day ago 82% | 1 day ago 71% |
| Aroon ODDS (%) | 1 day ago 76% | 1 day ago 68% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SNDL’s FA Score shows that 0 FA rating(s) are green while ZTS’s FA Score has 2 green FA rating(s).
- SNDL’s FA Score: 0 green, 5 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SNDL’s TA Score shows that 3 TA indicator(s) are bullish while ZTS’s TA Score has 4 bullish TA indicator(s).
- SNDL’s TA Score: 3 bullish, 6 bearish.
- ZTS’s TA Score: 4 bullish, 5 bearish.
Price Growth
SNDL (@Beverages: Alcoholic) experienced а -8.00% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was +5.23% for the same time period.
The average weekly price growth across all stocks in the @Beverages: Alcoholic industry was +6.53%. For the same industry, the average monthly price growth was -1.99%, and the average quarterly price growth was -24.95%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -6.04%. For the same industry, the average monthly price growth was -6.02%, and the average quarterly price growth was +11.12%.
Reported Earning Dates
SNDL is expected to report earnings on Nov 10, 2026.
ZTS is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Beverages: Alcoholic (+6.53% weekly)The alcoholic beverage market includes beer, wine, and spirits. From $230 billion in 2015, the industry has grown to around $250 billion by 2019. In recent years, alcoholic beverage makers have been looking to expand distribution and purchase channels, such as through online stores (e.g. e-commerce platform Drizly) and convenience stores. Anheuser-Busch In Bev and Diageo are major global alcoholic beverage companies, while U.S.-owned companies include Constellation Brands and Brown-Forman Corp. among several others.
@Pharmaceuticals: Generic (-6.04% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MOTI | 35.43 | -0.10 | -0.28% |
| VanEck Morningstar International Moat ETF (MOTI) | |||
| EFV | 78.45 | -0.40 | -0.51% |
| iShares MSCI EAFE Value ETF (EFV) | |||
| PTL | 271.63 | -4.77 | -1.73% |
| Inspire 500 ETF (PTL) | |||
| BUYO | 32.08 | -0.62 | -1.90% |
| KraneShares Man Buyout Beta Index ETF (BUYO) | |||
| FMAG | 35.79 | -0.71 | -1.94% |
| Fidelity Magellan ETF (FMAG) | |||